Riskpilot← Back to searchSign inGet full accessNORDIC BIOTECH GENERAL PARTNER ApS
APSIn liquidationCVR 26270367Strandvejen 125Activities of holding companies · NACE 6421Est. 2001— employees
Revenue 2024
DKK 40K
+426% vs 2023
EBITDA margin
100.0%
+426% vs 2023
Equity ratio
97.9%
Financial strength
Net profit 2024
DKK 67K
+92% vs 2023
| Revenue | DKK 40K | +426% |
| EBITDA | DKK 40K | +426% |
| Net profit | DKK 67K | +92% |
| Total assets | DKK 1,1M | +6% |
| Equity | DKK 1M | +7% |
| Employees | — | — |
Legal name
NORDIC BIOTECH GENERAL PARTNER ApS
CVR number
26270367
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
28. september 2001
Share capital
DKK 125.000
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er at være komplementar i Nordic Biotech K/S og Nordic Biotech Opportunity Fund K/S.
Address
Strandvejen 125
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21 | 22 | 21 | 18 | 16 | 2.362 | -417 | 16 | -765 | 16 | 12 | 8 | 40 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 21 | 22 | 21 | 18 | 16 | 2.362 | -417 | 16 | -765 | 16 | 12 | 8 | 40 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 21 | 22 | 21 | 18 | 16 | 2.362 | -417 | 16 | -765 | 16 | 12 | 8 | 40 |
| Net financials | -0 | -0 | -1 | -1 | -2 | -4 | -5 | -9 | -19 | -8 | -8 | 27 | 27 |
| Profit before tax | 21 | 22 | 21 | 16 | 15 | 2.357 | -421 | 7 | -784 | 8 | 4 | 35 | 67 |
| Tax | 5 | 5 | 5 | 4 | 3 | 519 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | 15 | 16 | 15 | 13 | 11 | 1.839 | -421 | 7 | -784 | 8 | 4 | 35 | 67 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 242 | 261 | 280 | 290 | 314 | 2.150 | 1.716 | 1.724 | 939 | 947 | 955 | 995 | 1.058 |
| Equity | 226 | 242 | 257 | 270 | 281 | 2.120 | 1.699 | 1.706 | 922 | 930 | 934 | 969 | 1.036 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 16 | 19 | 23 | 20 | 32 | 30 | 18 | 18 | 18 | 18 | 22 | 26 | 23 |
| Total debt | 16 | 19 | 23 | 20 | 32 | 30 | 18 | 18 | 18 | 18 | 22 | 26 | 23 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20122024
Equity ratio
97.9%
This company
38.2%
Market median
+156% vs market
20122024
Return on equity
6.5%
This company
18.4%
Market median
-65% vs market
20122024
Net profit margin
166.7%
This company
8.1%
Market median
+1958% vs market
20122024
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
20122024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BI Founder | Founder | 2001 | — | — |
CK Management | Management | 2010 | — | — |
JM Unofficial title | Unofficial title | 2026 | — | — |
V Founder | Founder | 2001 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2001 | — | — | |
| Board of Directors | 2001 | — | — | |
| Board of Directors | 2001 | — | — | |
| Chairman | 2001 | — | — | |
| Chairman | 2003 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
TECH GROWTH INVEST ApS | Company | 66.7% | 66.7% | 2025 |
C. HANSEN INVEST ApS | Company | 25.0% | 25.0% | 2002 |
| Individual | 25.0% | 25.0% | 2002 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Holdingselskabet af 1 januar 2016 ApSTECH GROWTH INVEST ApS
NORDIC BIOTECH GENERAL PARTNER ApS (this company)Board members of NORDIC BIOTECH GENERAL PARTNER ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| BVF/NexGen Investments, L.P | Founder | 0 companies |
| Christian Karsten Hansen | Management | 0 companies |
| Jakob Mosegaard Larsen | Unofficial title | 0 companies |
| VækstFonden | Founder | 0 companies |
| Claus Tycho Bræstrup | Board of Directors | 0 companies |
| Maja Kirstine Elsøe | Board of Directors | 0 companies |
| Matthew Daniel Perry | Board of Directors | 0 companies |
| Lars Grønborg Eskesen | Chairman | 0 companies |
| Florian Schønharting | Chairman | 0 companies |